ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis
PAMOCOS
1 other identifier
observational
183
1 country
8
Brief Summary
COVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2020
Shorter than P25 for all trials
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 7, 2020
CompletedFirst Submitted
Initial submission to the registry
July 17, 2020
CompletedFirst Posted
Study publicly available on registry
August 21, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 29, 2021
CompletedAugust 5, 2021
August 1, 2021
8 months
July 17, 2020
August 4, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.
Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.
comparison to day 1 and day 3
mortality at day 28 and day 90.
mortality at day 28 and day 90.
admission until day 90
Secondary Outcomes (2)
Association between MR-ProADM and mortality at day 28.
admission until day 28
Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28.
admission until day 28
Interventions
Dosage of MR-pro-ADM
Eligibility Criteria
Any adult patient admitted in the ICU with COVID-19 pneumonia
You may qualify if:
- Any adult patient admitted in the ICU with COVID-19 pneumonia
You may not qualify if:
- Pregnancy
- Legal reasons (patients under guardianship, curatorship)
- Patient's refusal
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (8)
Hospital of Arras
Arras, 62000, France
Hospital of Boulogne/mer
Boulogne-sur-Mer, 62200, France
Hospital of DOUAI
Douai, 59507, France
Hospital of Dunkerque
Dunkirk, 59240, France
Hospital Dr Schaffner
Lens, 62307, France
Hospital of Roubaix
Roubaix, 59100, France
Hospital of Tourcoing
Tourcoing, 59200, France
Hospitalier of Valenciennes
Valenciennes, 59300, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 17, 2020
First Posted
August 21, 2020
Study Start
July 7, 2020
Primary Completion
February 28, 2021
Study Completion
May 29, 2021
Last Updated
August 5, 2021
Record last verified: 2021-08
Data Sharing
- IPD Sharing
- Will not share